Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
about
Human Anti-Oxidation Protein A1M--A Potential Kidney Protection Agent in Peptide Receptor Radionuclide TherapyMedical management of metastatic medullary thyroid cancerRET mutations in a large indian family with medullary thyroid carcinoma.Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancersRevised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Integrin targeted delivery of radiotherapeutics.Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaKinase inhibitors for advanced medullary thyroid carcinoma.Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyThe joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursSequelae and survivorship in patients treated with (131)I-MIBG therapy2012 European thyroid association guidelines for metastatic medullary thyroid cancer.Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experienceYttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors.Prognostic and predictive markers in medullary thyroid carcinoma.Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.Targeted Therapy for Medullary Thyroid Cancer: A Review.Theranostics of Neuroendocrine Tumors.[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.Guidelines for the management of thyroid cancerEvolving paradigms for successful molecular imaging of medullary thyroid carcinoma
P2860
Q26773377-C6D8E7D2-7F1E-42AC-9DBF-7BB5460E4DF4Q27005897-845C21E0-AAB5-446F-A08B-96DF73A54A70Q34069272-C86C5ED6-B6BC-451A-AB65-E4FC2E895518Q34123724-A7E99B0B-21F0-43D9-BF26-4F7C24F61F97Q34468665-53E09980-C857-41D4-B5A3-DE9AD04E4F09Q34912696-422376C3-5290-4003-870A-5B45D15586F5Q34987688-2F574BED-8EE2-477F-AE52-B4D5301CEE9EQ35895485-48C8FEB9-4711-48C9-BD2F-A262BA0060A3Q36578624-8406D7D7-D8EF-4820-871D-E730C68E0D40Q36755905-9F607549-1B8F-4282-BFF0-333CE7D741D9Q37081870-0616A832-4304-4D2B-8B3B-9469546F1B2AQ37290840-E7816E4B-4D33-41BE-A772-487C80E0CA61Q37401654-C129F81A-D2B5-45A1-9692-CAFE570FEA86Q37402609-84524EA4-ED7F-4FF5-B0EB-E85CF09C21B8Q37417441-555AA14E-1CB8-49F0-BC4A-4E641699B4BCQ37812297-E5D7AB0B-15A7-4CE4-88AE-F8A9C595BBD3Q40616326-E0176A4C-F6CF-4B76-A87A-91ECC1CDF9F8Q43891433-36E41CA5-A8EF-491D-9A99-A76FA59E27E6Q44712034-CEE91D2C-E32F-4A73-B407-21470F969A95Q46111876-CF0377A7-B28D-4D7B-8122-DE03B013988CQ49328959-C1DF8306-84CC-4A72-853E-5AEA44B9A781Q49612068-6520CF73-5D19-4C7F-8405-1A2C0D38DD89Q51772441-0393E5CC-87C4-490A-83B5-32D972A6B3D3Q56554243-47528156-5966-4C3D-93B1-B3EB8D8BF0DEQ57998577-50ADA765-79DE-4431-BD50-FEC9251C170D
P2860
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Response to [90Yttrium-DOTA]-T ...... er: a phase II clinical trial.
@en
Response to [90Yttrium-DOTA]-T ...... er: a phase II clinical trial.
@nl
type
label
Response to [90Yttrium-DOTA]-T ...... er: a phase II clinical trial.
@en
Response to [90Yttrium-DOTA]-T ...... er: a phase II clinical trial.
@nl
prefLabel
Response to [90Yttrium-DOTA]-T ...... er: a phase II clinical trial.
@en
Response to [90Yttrium-DOTA]-T ...... er: a phase II clinical trial.
@nl
P2093
P1476
Response to [90Yttrium-DOTA]-T ...... er: a phase II clinical trial.
@en
P2093
Beat Müller
Christian Schindler
Christoph Rochlitz
Daniel Oertli
Fabienne Iten
Helmut R Mäcke
Jan Müller-Brand
P304
P356
10.1158/1078-0432.CCR-07-0935
P407
P433
P577
2007-11-01T00:00:00Z